What factors do you look at while deciding between a daratumumab-based quadruplet induction versus standard triplet induction such as VRd for newly diagnosed MM?

Answer from: Medical Oncologist at Academic Institution

This is becoming an increasingly thorny issue. A few guidelines to keep in mind:1) Dara-VRd has only been studied (thus far) in transplant-eligible patients. So this discussion of Dara-VRd vs. VRd is hard to apply to patients without intent for transplant. 2) When you look at the CASSIOPEIA and...

Comments

Medical Oncologist at Winship Cancer Institute of Emory University
I agree that the benefit of 4-drug induction is mo...

Medical Oncologist at ProMedica Flower Hospital
@Ben Derman, for patients with high risk cytogenet...

Medical Oncologist at University of Chicago
If the patient does not have significant neuropath...

Medical Oncologist at Upper Chesapeake Hematology Oncology
What do you offer for induction for a standard ris...

at The Robert Larner, M.D. College of Medicine at The University of Vermont
@Lillian Man - Yes! The MAIA trial confirms the OS...

Medical Oncologist at Texas Oncology Dallas
What regimen do you favor in someone with newly di...

Answer from: at Community Practice

I agree with Dr. @Derman's approach. With the Phase 2 GRIFFIN data that we do have available, I prefer to use Dara-RVd for our transplant-eligible population.For older patients who are not transplant-eligible, we have good phase 3 data from the MAIA trial to support the use of Dara-Rd (plus an accep...

Please select the option that best describes you:

What factors do you look at while deciding between a daratumumab-based quadruplet induction versus standard triplet induction such as VRd for newly diagnosed MM?

Related Questions